
Catch up - OPEC+ does not have "the bandwidth to prop prices much higher"
High school basketball teams help raise money for cancer research
Lawyer Says Ex-Temple Basketball Standout Hysier Miller Met With NCAA for Hours Amid Gambling ProbeGuessing game over Trump's Treasury pick adds to US bond market's negative mood
8 Thanksgiving mistakes: Frozen or overcooked turkey, too many sides and other common holiday miscues— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA , LLC — SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX ) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA , LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos. 9,561,229 and 9,974,794, which expire in 2035, are valid and would be infringed by Fresenius' proposed generic product. The district court decision concludes the litigation initiated in July 2022 in response to Fresenius' submission of an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval of a generic version of CINVANTI®. As a result of the decision, Heron will seek an order from the Court prohibiting Fresenius from launching its generic CINVANTI® until after the expiration of the patents in 2035. This decision is subject to appeal. "We are pleased with this anticipated result of the proceeding and will continue to vigorously defend the CINVANTI® patent estate in the future," said Craig Collard, Chief Executive Officer of Heron. "The team at Heron takes great pride in the result of our successful history of developing injectable products, which is demonstrated by the strength of our intellectual property and the performance of our innovative drugs like CINVANTI® in serving patients with serious unmet needs." About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400 SOURCE Heron Therapeutics, Inc.
Man Utd staring £10million black hole in the face as Sir Jim Ratcliffe slashes £40k donation to charity helping legendsHOUSTON (AP) — The Houston Texans made mistakes in every facet of the game Sunday against the Tennessee Titans to lose for the third time in four games. C.J. Stroud threw two interceptions, the defense gave up multiple big passing plays and Ka′imi Fairbairn missed a 28-yard field goal that would have tied it late in a 32-27 loss . Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week
TikTok files legal challenge of federal government's shutdown order45 years ago, an 11-year-old and his brother started a band. Redd Kross won’t quit
Korea lifts martial law, relieving some market uncertainty
Justice Department announces sweeping reforms to curb suicides in federal prisons and jailsCellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
Jordan Sears scores 25 points, Jalen Reed has double-double and LSU outlasts UCF 109-102 in 3OTElias Cato scores 23 as Central Arkansas tops UNC Asheville 92-83 in double OTCOLLEGE STATION, Texas (AP) — Wade Taylor IV had 15 points and a career-high 10 assists, and Zhuric Phelps had 12 points and 10 rebounds in No. 13 Texas A&M's 92-54 win over Abilene Christian on Saturday. Taylor's 15 points passed Vernon Smith, who scored 1,778 points at A&M from 1977-81, for second on Texas A&M's all-time scoring list. Taylor now has 1,779 career points and needs 212 more to pass Bernard King, who scored 1,990 points from 1999-2003, as Texas A&M’s all-time scoring leader. Taylor returned to action after he missed his first career game on Dec. 20 against Houston Christian. The Aggies (11-2) opened the game on a 7-0 run and never looked back. Texas A&M led 48-29 at halftime and ended the game on a 12-0 run over the final 5:24. Quion Williams led Abilene Christian (8-6) with 14 points. Abilene Christian: The Wildcats lost to Texas A&M 81-80 in November 2021 but were too overmatched this season to have a chance at an upset bid. Texas A&M: The Aggies closed nonconference play on a seven-game winning streak in Taylor’s return. The Aggies used a 14-0 run in the first half to build an 18-point lead. Texas A&M guard CJ Wilcher made three straight 3-pointers during the run, including back-to-back from the right wing during fastbreaks. The Wildcats never got within single digits again. Texas A&M continued to show its depth as the Aggies had 45 bench points. Wilcher led the way with a season-high 14 points and forward Andersson Garcia had 12. Twelve players saw action and all 12 scored. The Aggies start Southeastern Conference play against rival Texas on Jan. 4. Abilene Christian closes nonconference action on Dec. 31 at home against Stephen F. Austin. Get poll alerts and updates on AP Top 25 basketball throughout the season. Sign up here. AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Businesses across the globe are scrambling — even trying to frontload orders to the United States — as they stare down the second inauguration of President-elect Donald Trump and the possibility he'll follow through on enacting steep tariffs . Trump recently threatened to impose tariffs on U.S. allies and demanded that the European Union close its trade gap with the United States. The president-elect told the EU to reduce the gap by buying oil and gas or face tariffs, which he's also threatened to levy on Canada , China and Mexico. “I told the European Union that they must make up their tremendous deficit with the United States by the large scale purchase of our oil and gas," Trump posted on Truth Social earlier this month. "Otherwise, it is TARIFFS all the way." Companies such as Hangzhou Skytech Outdoor Co. in Shanghai and a winemaker in Germany are among businesses frantically preparing for Trump, with the former hastily trying to find other markets to tap into and the latter sprinting to fill as many orders as possible before Jan. 20, Bloomberg reported. ALSO READ: Why ABC settled a case they knew they would win — and why the Lincoln Project didn't “We’re still in the freakout period,” Robert Krieger, president of the customs brokerage and logistics advisory firm Krieger Worldwide, told the publication. “There’s about to be a king tide in the supply chain.” Businesses worldwide are in panic mode as they brace for possible tariffs , according to the report. JLab has frozen hirings until mid-2025 and mulled price hikes for its headphones and other wireless products if tariffs are imposed . Bloomberg noted that mentions of tariffs on company conference calls have skyrocketed in November and December, higher than at any time in the last four years, eclipsing the previous high of March 2020. “If you wait too long, you’re going to find yourself trying to make the transition in a pinch,” Zipfox CEO Raine Mahdi told the outlet. “This time you’re not catching the tail end of the Trump administration, you’re catching the entire thing and with a new wrath.”